Lilly trials boost amyloid link to Alzheimer’s-analysis
(Reuters) - Levels of a protein believed to be a main cause of Alzheimer's disease rose in the blood of patients treated with Eli Lilly's experimental drug in late-stage trials,...
Home > Reviews
All Stories
Lilly trials boost amyloid link to Alzheimer’s-analysis
(Reuters) - Levels of a protein believed to be a main cause of Alzheimer's disease rose in the blood of patients treated with Eli Lilly's experimental drug in late-stage trials,...
Edwards Lifesciences’ heart valve wins widened approval
(Reuters) - Edwards Lifesciences Corp said U.S. health regulators widened the approved use of its Sapien artificial heart valve to include patients who are eligible for surgery but at high...
Edwards Lifesciences’ heart valve wins widened approval
(Reuters) - Edwards Lifesciences Corp said U.S. health regulators widened the approved use of its Sapien artificial heart valve to include patients who are eligible for surgery but at high...
Abbott says kidney drug study halted; shares drop
(Reuters) - Abbott Laboratories Inc said its partner, Reata Pharmaceuticals, was discontinuing a late-stage trial of their potential blockbuster treatment for chronic kidney disease and diabetes based on safety concerns...
Abbott says kidney drug study halted; shares drop
(Reuters) - Abbott Laboratories Inc said its partner, Reata Pharmaceuticals, was discontinuing a late-stage trial of their potential blockbuster treatment for chronic kidney disease and diabetes based on safety concerns...
Alzheimer’s drug shows promise
Eli Lilly and Co said its experimental Alzheimer's drug led to a 34 percent reduction in memory decline for patients with mild symptoms over a period of 18 months, giving...
Alzheimer’s drug shows promise
Eli Lilly and Co said its experimental Alzheimer's drug led to a 34 percent reduction in memory decline for patients with mild symptoms over a period of 18 months, giving...
FDA approves Sanofi/Regeneron colon cancer drug
(Reuters) - The U.S. Food and Drug Administration said on Friday that it had approved the Sanofi SA and Regeneron Pharmaceuticals Inc drug Zaltrap for patients with metastatic colorectal cancer...
FDA approves Sanofi/Regeneron colon cancer drug
(Reuters) - The U.S. Food and Drug Administration said on Friday that it had approved the Sanofi SA and Regeneron Pharmaceuticals Inc drug Zaltrap for patients with metastatic colorectal cancer...